The Central Government has submitted a significant proposal before the Supreme Court of India, aiming to implement a 30 percent trade margin cap on life-saving cancer medicines. This move is designed to curb excessive markups and ensure that these critical drugs remain affordable for patients while maintaining a reasonable profit margin for the trade chain. Solicitor General Tushar Mehta, representing the Centre, informed the apex court that a comprehensive list of cancer drugs subject to this 30 percent trade margin limit will be released soon. This list isn't intended to be static; the government plans to update it periodically based on evolving market conditions and public health requirements, adding new drugs as necessary while excluding those that are already affordable.
Supreme Court Advocates for Broader Price Control
During the proceedings, the Supreme Court emphasized the necessity for a more extensive investigation into drug pricing across the pharmaceutical sector, while the bench, comprising Justice Vikram Nath and Justice Sandeep Mehta, observed that the regulatory process shouldn't be confined solely to anti-cancer medications but should encompass the entire pharmaceutical market. The court raised serious concerns regarding the current pricing structures, questioning why the Maximum Retail Price (MRP) for certain drugs was set at levels as high as 400 times the cost for sellers. The bench noted that any decision to apply caps on some drugs while leaving others unregulated must be justified by clear benefits to the consumers. The court expressed its desire to see the price of the entire drug market regulated rather than focusing on a small segment.
Economic Impact and Consumer Benefits
The government's proposal is expected to bring substantial relief to patients. According to the estimates provided to the court, the implementation of a 30 percent trade margin cap could lead to a reduction in the MRP of cancer drugs by 20 to 70 percent. This reduction is projected to result in annual savings of approximately 2500 crore rupees for consumers. The Centre argued that a 30 percent cap represents a balanced margin that ensures both affordability for patients and the continued availability of medicines in the market. This proposal comes in response to a petition seeking to regulate the initial prices of non-scheduled drugs and to set price limits on medical devices.
Balancing Pricing and Availability
Solicitor General Tushar Mehta argued that the government's approach must be balanced to ensure that while prices are controlled, the availability of drugs isn't compromised. He stated that there must be a balance between pricing and availability to ensure that a market remains available for these medicines. The Centre expressed caution against excessive intervention, warning that it could damage the market, lead to a decrease in drug availability, and make distribution more difficult. Mehta pointed out that India already has some of the lowest drug prices in the world and stated that the government doesn't wish to control the entire range of medicines excessively. The court had previously suggested applying a standard 16 percent retail margin, which is currently fixed for scheduled drugs under the Drugs (Prices Control) Order, 2013, to all non-scheduled and hospital-supplied medicines. However, the government maintains that its proposed 30 percent trade margin cap is a more suitable measure for the current market dynamics.
Next Steps in the Legal Process
The Supreme Court has scheduled the next hearing for this matter on 27 October. During the upcoming session, the court is expected to further examine the government's proposal and the broader implications for the pharmaceutical industry. The bench has made it clear that it views the current cap on anti-cancer drugs as a small step and intends to look at the pricing of the entire market. The government will need to justify its selection of drugs for the cap and explain why certain medications are excluded, ensuring that the final regulatory framework is in the best interest of the consumers. The outcome of the hearing on 27 October will be crucial in determining the future of drug pricing and accessibility in India.